Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy
JAMA Dermatology · 01.03.2024 · 160 (3) · 290
DOI: 10.1001/jamadermatol.2023.5679 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Dermatology, erschienen am 01.03.2024. Verfasst von Billal Tedbirt und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France. Hauptthemen laut MEDLINE: Pemphigus. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available.
Objective
To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. Design, Setting, and Participants This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015. Exposure Patients were initially randomized in the rituximab plus prednisone group or prednisone-alone group. Main outcomes and measures The primary outcome was the 5- and 7-year disease-free survival (DFS) without corticosteroids, assessed by Kaplan-Meier curves. Secondary outcomes were occurrence of relapse, occurrence of severe adverse events (SAEs), and evolution of antidesmoglein (Dsg) antibody enzyme-linked immunosorbent assay values to predict long-term relapse.
Results
Of the 90 patients in the Ritux 3 trial, 83 were evaluated at the end of follow-up study visit (44 in the rituximab plus prednisone group; 39 in the prednisone-alone group) with a median (IQR) follow-up of 87.3 (79.1-97.5) months. Forty-three patients (93%) from the rituximab plus prednisone and 17 patients (39%) from the prednisone-alone group had achieved complete remission without corticosteroids at any time during the follow-up. Patients from the rituximab group had much longer 5- and 7-year DFS without corticosteroids than patients from the prednisone-alone group (76.7% and 72.1% vs 35.3% and 35.3%, respectively; P < .001), and had about half the relapses (42.2% vs 83.7%; P < .001). Patients who received rituximab as second-line treatment had shorter DFS than patients treated as first line ( P = .007). Fewer SAEs were reported in the rituximab plus prednisone group compared with the prednisone-alone group, 31 vs 58 respectively, corresponding to 0.67 and 1.32 SAEs per patient, respectively ( P = .003). The combination of anti-Dsg1 values of 20 or more IU/mL and/or anti-Dsg3 values of 48 or more IU/mL yielded 0.83 positive predictive value and 0.94 negative predictive value to predict long-term relapse. Conclusions and Relevance In this secondary analysis of the Ritux 3 trail, first-line treatment of patients with pemphigus with the Ritux 3 regimen was associated with long-term sustained complete remission without corticosteroid therapy without any additional maintenance infusion of rituximab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France.
- Department of Biostatistics and Clinical Research, CHU Rouen, Rouen, France.
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France.
- Department of Dermatology, University of Saint-Étienne, Saint-Étienne, France.
- Department of Dermatology, Bichat Hospital, University of Paris 10, Paris, France.
- Department of Dermatology, University of Amiens, Amiens, France.
Zitieren
APA
Tedbirt, B., Maho-Vaillant, M., Houivet, E., Mignard, C., Golinski, M. L., Calbo, S., Prost-Squarcioni, C., Labeille, B., Picard-Dahan, C., Chaby, G., Richard, M. A., Tancrede-Bohin, E., Duvert-Lehembre, S., Delaporte, E., Bernard, P., Caux, F., Alexandre, M., Musette, P., Ingen-Housz-Oro, S., …, & French Reference Center for Autoimmune Blistering Diseases MALIBUL (2024). Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy. JAMA Dermatology, 160(3), 290. https://doi.org/10.1001/jamadermatol.2023.5679
Vancouver
Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, et al. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy. JAMA Dermatology. 2024;160(3):290. doi:10.1001/jamadermatol.2023.5679
BibTeX
@article{Tedbirt2024,
author = {Tedbirt, Billal and Maho-Vaillant, Maud and Houivet, Estelle and Mignard, Claire and Golinski, Marie-Laure and Calbo, Sébastien and Prost-Squarcioni, Catherine and Labeille, Bruno and Picard-Dahan, Catherine and Chaby, Guillaume and Richard, Marie-Aleth and Tancrede-Bohin, Emmanuelle and Duvert-Lehembre, Sophie and Delaporte, Emmanuel and Bernard, Philippe and Caux, Frédéric and Alexandre, Marina and Musette, Philippe and Ingen-Housz-Oro, Saskia and Vabres, Pierre and Quereux, Gaëlle and Dupuy, Alain and Debarbieux, Sébastien and Avenel-Audran, Martine and D'Incan, Michel and Bédane, Christophe and Bénéton, Nathalie and Jullien, Denis and Dupin, Nicolas and Misery, Laurent and Machet, Laurent and Beylot-Barry, Marie and Dereure, Olivier and Sassolas, Bruno and Benichou, Jacques and Joly, Pascal and Hébert, Vivien and French Reference Center for Autoimmune Blistering Diseases MALIBUL, French Reference Center for Autoimmune Blistering Diseases MALIBUL},
title = {Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy},
journal = {JAMA Dermatology},
year = {2024},
volume = {160},
number = {3},
pages = {290},
doi = {10.1001/jamadermatol.2023.5679}
}
EUVIMED